2 * The FDA review of this NDA is anticipated to be completed by the end of this year
It works as a GLP-1 receptor agonist, meaning it helps reduce appetite and increases feelings of fullness, leading to significant weight reduction
Take the timing of your medications and try to associate it with some other healthy activities like maintaining a balanced diet and enough regular exercise
Some users have signed up for these services, submitted credit card data for a relatively modest membership fee, and woken up to massive credit card charges for GLP-1 meds they did not request

Approval (2017) Novo Nordisk Press Release (18th October, 2025): FDA Approves Novo Nordisk's Oral Semaglutide For Cardiovascular (CV) Risk Reduction In Adults With Type 2 Diabetes Who Are At High Risk, Including Those Who Have Not Had A Prior CV Event Once-Weekly Semaglutide in Adults With Overweight or Obesity (March 2021) Efficacy And Safety Of Once-Weekly Semaglutide 20 Mg Versus 10 Mg In Patients With Type 2 Diabetes (SUSTAIN FORTE): A Double-Blind, Randomised, Phase 3b Trial (July 19, 2021) Oral Semaglutide Versus Subcutaneous Liraglutide And Placebo In Type 2 Diabetes (PIONEER 4): A Randomised, Double-Blind, Phase 3a Trial Novo Nordisk Press Release (21st October, 2024) Novo Nordisk A/S: Oral Semaglutide Demonstrates A 14% Reduction In Risk Of Major Adverse Cardiovascular Events In Adults With Type 2 Diabetes In The SOUL Trial Efficacy And Safety Of Once-Weekly Semaglutide 20 Mg Versus 10 Mg In Patients With Type 2 Diabetes (Sustain Forte): A Double-Blind, Randomised, Phase 3b Trial Metabolic Dysfunction-Associated Steatohepatitis And Progression To Hepatocellular Carcinoma: A Literature Review (March 20th, 2024)
